Pfizer (PFE) Revenue & Revenue Breakdown
Pfizer Revenue Highlights
Latest Revenue (Y)
$58.50B
Latest Revenue (Q)
$13.28B
Main Segment (Y)
Biopharma Segment
Main Geography (Y)
UNITED STATES
Pfizer Revenue by Period
Pfizer Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $58.50B | -41.70% |
| 2022-12-31 | $100.33B | 23.43% |
| 2021-12-31 | $81.29B | 93.97% |
| 2020-12-31 | $41.91B | -19.02% |
| 2019-12-31 | $51.75B | -3.54% |
| 2018-12-31 | $53.65B | 2.10% |
| 2017-12-31 | $52.55B | -0.53% |
| 2016-12-31 | $52.82B | 8.13% |
| 2015-12-31 | $48.85B | -1.52% |
| 2014-12-31 | $49.60B | -3.84% |
| 2013-12-31 | $51.58B | -12.55% |
| 2012-12-31 | $58.99B | -12.52% |
| 2011-12-31 | $67.42B | -0.57% |
| 2010-12-31 | $67.81B | 35.59% |
| 2009-12-31 | $50.01B | 3.55% |
| 2008-12-31 | $48.30B | -0.25% |
| 2007-12-31 | $48.42B | 0.10% |
| 2006-12-31 | $48.37B | -5.71% |
| 2005-12-31 | $51.30B | -2.32% |
| 2004-12-31 | $52.52B | 16.22% |
| 2003-12-31 | $45.19B | 39.59% |
| 2002-12-31 | $32.37B | 0.35% |
| 2001-12-31 | $32.26B | 9.08% |
| 2000-12-31 | $29.57B | 82.51% |
| 1999-12-31 | $16.20B | 19.64% |
| 1998-12-31 | $13.54B | 8.32% |
| 1997-12-31 | $12.50B | 10.60% |
| 1996-12-31 | $11.31B | 12.82% |
| 1995-12-31 | $10.02B | 21.01% |
| 1994-12-31 | $8.28B | 10.75% |
| 1993-12-31 | $7.48B | - |
Pfizer generated $58.50B in revenue during NA 2023, up -41.70% compared to the previous quarter, and up 109.04% compared to the same period a year ago.
Pfizer Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $13.28B | -10.73% |
| 2024-03-31 | $14.88B | 4.42% |
| 2023-12-31 | $14.25B | 7.69% |
| 2023-10-01 | $13.23B | 3.91% |
| 2023-07-02 | $12.73B | -30.35% |
| 2023-04-02 | $18.28B | -24.73% |
| 2022-12-31 | $24.29B | 7.30% |
| 2022-10-02 | $22.64B | -18.40% |
| 2022-07-03 | $27.74B | 8.11% |
| 2022-04-03 | $25.66B | 7.65% |
| 2021-12-31 | $23.84B | -1.06% |
| 2021-10-03 | $24.09B | 26.96% |
| 2021-07-04 | $18.98B | 30.14% |
| 2021-04-04 | $14.58B | 24.80% |
| 2020-12-31 | $11.68B | -3.68% |
| 2020-09-27 | $12.13B | 2.80% |
| 2020-06-28 | $11.80B | -1.89% |
| 2020-03-29 | $12.03B | -5.20% |
| 2019-12-31 | $12.69B | 0.06% |
| 2019-09-29 | $12.68B | -4.40% |
| 2019-06-30 | $13.26B | 1.11% |
| 2019-03-31 | $13.12B | -6.14% |
| 2018-12-31 | $13.98B | 5.10% |
| 2018-09-30 | $13.30B | -1.25% |
| 2018-07-01 | $13.47B | 4.34% |
| 2018-04-01 | $12.91B | -5.82% |
| 2017-12-31 | $13.70B | 4.06% |
| 2017-10-01 | $13.17B | 2.11% |
| 2017-07-02 | $12.90B | 0.92% |
| 2017-04-02 | $12.78B | -6.22% |
| 2016-12-31 | $13.63B | 4.46% |
| 2016-10-02 | $13.04B | -0.78% |
| 2016-07-03 | $13.15B | 1.09% |
| 2016-04-03 | $13.01B | -7.42% |
| 2015-12-31 | $14.05B | 16.22% |
| 2015-09-27 | $12.09B | 1.97% |
| 2015-06-28 | $11.85B | 9.10% |
| 2015-03-29 | $10.86B | -17.18% |
| 2014-12-31 | $13.12B | 6.12% |
| 2014-09-28 | $12.36B | -3.23% |
| 2014-06-29 | $12.77B | 12.51% |
| 2014-03-30 | $11.35B | -16.26% |
| 2013-12-31 | $13.56B | 7.24% |
| 2013-09-29 | $12.64B | -2.54% |
| 2013-06-30 | $12.97B | -3.90% |
| 2013-03-31 | $13.50B | -10.41% |
| 2012-12-31 | $15.07B | 7.81% |
| 2012-09-30 | $13.98B | 0.06% |
| 2012-07-01 | $13.97B | 0.89% |
| 2012-04-01 | $13.85B | -17.32% |
| 2011-12-31 | $16.75B | 0.82% |
| 2011-10-02 | $16.61B | 0.75% |
| 2011-07-03 | $16.48B | 2.88% |
| 2011-04-03 | $16.02B | -8.75% |
| 2010-12-31 | $17.56B | 9.79% |
| 2010-10-03 | $15.99B | -6.64% |
| 2010-07-04 | $17.13B | 3.35% |
| 2010-04-04 | $16.58B | 0.24% |
| 2009-12-31 | $16.54B | 42.30% |
| 2009-09-27 | $11.62B | 5.80% |
| 2009-06-28 | $10.98B | 1.08% |
| 2009-03-29 | $10.87B | -11.98% |
| 2008-12-31 | $12.35B | 3.12% |
| 2008-09-28 | $11.97B | -1.29% |
| 2008-06-29 | $12.13B | 2.37% |
| 2008-03-30 | $11.85B | -7.94% |
| 2007-12-31 | $12.87B | - |
Pfizer generated $13.28B in revenue during Q2 2024, up -10.73% compared to the previous quarter, and up 72.66% compared to the same period a year ago.
Pfizer Revenue Breakdown
Pfizer Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Biopharma Segment | $57.19B | $98.99B | $6.50B | - | - |
| Comirnaty | - | $3.10B | - | - | - |
| Total Alliance Biopharmaceuticals | - | $8.54B | $7.65B | $5.42B | - |
| Total Biosimilars | - | - | $2.34B | $1.53B | - |
| Total Sterile Injectable Pharmaceuticals | - | - | $5.75B | $5.32B | - |
| Consumer Healthcare | - | - | - | - | $2.10B |
Pfizer's latest annual revenue breakdown by segment (product or service), as of Dec 23: Biopharma Segment (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Apr 23 | Dec 22 | Oct 22 | Jul 22 | Apr 22 | Dec 21 | Oct 21 | Jul 21 | Apr 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharma Segment | $2.07B | $2.17B | $13.87B | $12.93B | $1.72B | $1.25B | $1.61B | $1.81B | $1.38B | - | - | - | - | - | - | - | - | - | - | - |
| Comirnaty | - | - | - | $140.00M | $300.00M | $1.70B | $600.00M | $68.00M | $800.00M | - | - | - | - | - | - | - | - | - | - | - |
| Total Alliance Biopharmaceuticals | - | - | - | - | $1.97B | $1.69B | $2.32B | $2.31B | $1.93B | $2.07B | $1.88B | $1.77B | - | - | - | - | - | - | - | - |
| Total Sterile Injectable Pharmaceuticals | - | - | - | - | - | - | - | - | $1.29B | $1.33B | $1.44B | $1.44B | $1.38B | $1.48B | - | - | - | - | - | - |
| Total Biosimilars | - | - | - | - | - | - | - | - | $580.00M | $605.00M | $680.00M | $575.00M | $559.00M | $530.00M | - | - | - | - | - | - |
| Biopharma, Upjohn And Consumer Healthcare Segments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $12.13B | $11.80B | $12.03B | $1.33B | $12.68B | $13.26B |
| Upjohn Segment | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $76.00M | $79.00M | $78.00M | $77.00M | $74.00M | $73.00M |
| Consumer Healthcare | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $377.00M | $862.00M |
Pfizer's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Biopharma Segment (100.00%).
Pfizer Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| UNITED STATES | $27.09B | $42.47B | $29.75B | $21.71B | $23.85B |
| Developed Europe | $11.65B | $21.98B | - | - | - |
| Developed Rest Of World | $7.76B | $15.78B | - | - | - |
| Emerging Markets | $12.00B | $20.10B | - | - | - |
Pfizer's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (46.31%), Emerging Markets (20.51%), Developed Europe (19.92%), and Developed Rest Of World (13.27%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Apr 23 | Oct 22 | Jul 22 | Apr 22 | Dec 21 | Oct 21 | Jul 21 | Apr 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emerging Markets | $2.23B | $2.17B | $2.31B | $2.37B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| UNITED STATES | $7.89B | $9.51B | $4.59B | $7.80B | $6.18B | $8.51B | $13.85B | $11.22B | $8.92B | $7.48B | $7.08B | $7.59B | $7.60B | $4.94B | $5.72B | $5.40B | $5.65B | $5.49B | $5.85B | $6.33B |
| Developed Rest Of World | $3.16B | $3.20B | $2.91B | $1.07B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Developed Europe | - | - | $4.43B | $1.98B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Pfizer's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (59.41%), Developed Rest Of World (23.82%), and Emerging Markets (16.77%).
Pfizer Peer Comparison by Revenue
PFE Revenue FAQ
What is Pfizer’s yearly revenue?
Pfizer's yearly revenue for 2023 was $58.5B, representing a decrease of -41.70% compared to 2022. The company's yearly revenue for 2022 was $100.33B, representing an increase of 23.43% compared to 2021. PFE's yearly revenue for 2021 was $81.29B, representing an increase of 93.97% compared to 2020.
What is Pfizer’s quarterly revenue?
Pfizer's quarterly revenue for Q2 2024 was $13.28B, a -10.73% decrease from the previous quarter (Q1 2024), and a 4.31% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $14.88B, a 4.42% increase from the previous quarter (Q4 2023), and a -18.61% decrease year-over-year (Q1 2023). PFE's quarterly revenue for Q4 2023 was $14.25B, a 7.69% increase from the previous quarter (Q3 2023), and a -41.34% decrease year-over-year (Q4 2022).
What is Pfizer’s revenue growth rate?
Pfizer's revenue growth rate for the last 3 years (2021-2023) was -28.04%, and for the last 5 years (2019-2023) was 13.04%.
What are Pfizer’s revenue streams?
Pfizer's revenue streams in c 23 are Biopharma Segment
What is Pfizer’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Pfizer was Biopharma Segment. This segment made a revenue of $57.19B, representing 100.00% of the company's total revenue.